BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 18444984)

  • 21. Meta-analysis: amantadine may lower the efficacy of pegylated interferon plus ribavirin in treatment-naive hepatitis C genotype 1 patients.
    Chen J; Shi J; Xie WF; Zeng X; Lin Y
    Int J Infect Dis; 2012 Oct; 16(10):e748-52. PubMed ID: 22836046
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of interferon-based antiviral therapy in patients with chronic hepatitis C infected with genotype 5: a meta-analysis of two large prospective clinical trials.
    D'Heygere F; George C; Van Vlierberghe H; Decaestecker J; Nakad A; Adler M; Delwaide J; Laureys A; Nevens F
    J Med Virol; 2011 May; 83(5):815-9. PubMed ID: 21412790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated interferon-α2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 1 receiving hemodialysis: a randomized trial.
    Liu CH; Huang CF; Liu CJ; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Chen SI; Lin JW; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
    Ann Intern Med; 2013 Dec; 159(11):729-38. PubMed ID: 24297189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meta-analysis of factors associated with sustained viral response in patients on hemodialysis treated with standard or pegylated interferon for hepatitis C infection.
    Alavian SM; Tabatabaei SV
    Iran J Kidney Dis; 2010 Jul; 4(3):181-94. PubMed ID: 20622305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of hepatitis C virus infection in patients with end-stage renal disease.
    Liu CH; Kao JH
    J Gastroenterol Hepatol; 2011 Feb; 26(2):228-39. PubMed ID: 21261711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy with interferon-alpha and ribavirin in patients with dual hepatitis B and hepatitis C virus infection.
    Hung CH; Lee CM; Lu SN; Wang JH; Tung HD; Chen CH; Changchien CS
    J Gastroenterol Hepatol; 2005 May; 20(5):727-32. PubMed ID: 15853986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy (interferon alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and systematic review.
    Shepherd J; Waugh N; Hewitson P
    Health Technol Assess; 2000; 4(33):1-67. PubMed ID: 11134916
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: A retrospective study.
    Akhil MS; Kirushnan B; Martin M; Arumugam K; Ganesh Prasad NK; Ravichandran R
    Nephrology (Carlton); 2018 May; 23(5):446-452. PubMed ID: 28339162
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: a meta-analysis of randomized controlled trials.
    Zhang CH; Xu GL; Jia WD; Li JS; Ma JL; Ge YS
    Int J Cancer; 2011 Sep; 129(5):1254-64. PubMed ID: 21710498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter study of pegylated interferon α-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study.
    Kikuchi K; Akiba T; Nitta K; Masakane I; Ando R; Izumi N; Atsukawa M; Yamazaki C; Kato F; Hotta N; Tominaga Y; Orito E; Hora K; Nagasawa M; Kasahara H; Kawaguchi M; Kimura H; Ikebe N; Kawanishi H; Moriishi M; Shigemoto K; Harada T; Hirakata H; Watanabe H; Nosaki T; Tsubouchi H; Imawari M; Akizawa T
    Ther Apher Dial; 2014 Dec; 18(6):603-11. PubMed ID: 25196061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany.
    Dintsios CM; Haverkamp A; Wiegand J; Gerlach T; Wedemeyer H; Pape G; Manns MP; Krauth C
    Eur J Gastroenterol Hepatol; 2010 Mar; 22(3):278-88. PubMed ID: 19550347
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of individualized treatment for hepatitis C patients in the real world.
    Chen TM; Huang PT; Lin CH; Tsai MH; Lin LF; Liu CC; Ho KS; Tung JN
    J Gastroenterol Hepatol; 2010 Jan; 25(1):61-9. PubMed ID: 19780879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant.
    Fabrizi F; Martin P; Messa P
    Kidney Int; 2016 May; 89(5):988-994. PubMed ID: 27083277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients.
    Bader T; Hughes LD; Fazili J; Frost B; Dunnam M; Gonterman A; Madhoun M; Aston CE
    J Viral Hepat; 2013 Sep; 20(9):622-7. PubMed ID: 23910646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group.
    Keeffe EB; Hollinger FB
    Hepatology; 1997 Sep; 26(3 Suppl 1):101S-107S. PubMed ID: 9305673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.
    García-Agudo R; Aoufi-Rabih S; Salgueira-Lazo M; González-Corvillo C; Fabrizi F
    Int J Artif Organs; 2018 Jul; 41(7):363-370. PubMed ID: 29582685
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis: anti-viral therapy of hepatitis B virus-associated glomerulonephritis.
    Fabrizi F; Dixit V; Martin P
    Aliment Pharmacol Ther; 2006 Sep; 24(5):781-8. PubMed ID: 16918881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pegylated interferon alfa-2a monotherapy for hemodialysis patients with acute hepatitis C.
    Liu CH; Liang CC; Liu CJ; Lin JW; Chen SI; Hung PH; Tsai HB; Lai MY; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2010 Sep; 51(5):541-9. PubMed ID: 20645865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.